NCT05160922 2025-09-03Crizotinib Continuation Clinical StudyPfizerPhase 4 Active not recruiting27 enrolled
NCT02487316 2016-12-30A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With CrizotinibPeking UniversityPhase 4 Withdrawn